Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Preservative-Free eye drops take on glaucoma in Head-to-Head trial

NCT ID NCT06394973

Disease control Sponsor: Laboratoires Thea Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed Phase 2 trial tested two strengths of a new eye drop called T4090 against the existing drug Rhopressa in 161 adults with open-angle glaucoma or ocular hypertension. The goal was to see which better lowers eye pressure over 7 weeks. Participants used one drop daily in each eye. The study aims to find a safe and effective alternative for managing these chronic eye conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
T4090 (kinezodianone hydrochloride) eye drops
What this could lead to
If successful, T4090 could offer a new preservative-free option to lower eye pressure in glaucoma patients.
What could go wrong
This is a small Phase 2 trial, so results may not confirm effectiveness or safety. It only compares to one existing drug and may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

161 people

The number who actually took part.

Started

Aug 2024

Finished

Nov 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Main Inclusion Criteria: * Patient (male or female) ≥18 years old * Patient with Open Angle Glaucoma or Ocular Hypertension in both eyes * Informed consent dated and signed. Main Exclusion Criteria: * Secondary Open Agle Glaucoma (ex. Pseudoexfoliation, Pigmentary glaucoma) * Advanced stage of glaucoma * History of ocular trauma, eye infection, or/and ocular clinically significant inflammation within the 6 previous months. * Known or suspected hypersensitivity to one of the components of the IMPs or other product used in the clinical study * Pregnancy (confirmed with a positive urine pregnancy test) or breast-feeding.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glaucoma ocular hypertension open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glaucoma Ocular hypertension

Contacts and locations

Locations

  • Alterman, Modi and Wolter Ophthalmic Surgeons

    Poughkeepsie, New York, 12603, United States

  • Arizona Advanced Eye Research Institute

    Glendale, Arizona, 85306, United States

  • Coastal Research Associates, LLC

    Roswell, Georgia, 30076, United States

  • DCT-Shah Research, LLC sba Discovery Clinical Trials

    Mission, Texas, 78572, United States

  • East Coast Institute for Research, LLC

    Jacksonville, Florida, 32256, United States

  • Emerson Clinical Research Institute

    Falls Church, Virginia, 22046, United States

  • Eye Research Foundation

    Newport Beach, California, 92663, United States

  • Glaucoma Associates of Texas

    Dallas, Texas, 75231, United States

  • Global Research Management, Inc.

    Glendale, California, 91204, United States

  • Houston Eye Associates

    Houston, Texas, 53719, United States

  • Houston Eye Associates

    Houston, Texas, 77008, United States

  • James D. Branch, MD

    Winston-Salem, North Carolina, 27101, United States

  • Keystone Research

    Austin, Texas, 78731, United States

  • Mild Florida Eye Center

    Mt. Dora, Florida, 32757, United States

  • North Bay Eye Associates

    Petaluma, California, 94954, United States

  • Piedmont Eye Center

    Lynchburg, Virginia, 24502, United States

  • Sacramento Eye Consultants, A Medical Corporation

    Sacramento, California, 95815, United States

  • Segal Drug Trials, Inc

    Delray Beach, Florida, 33484, United States

  • Seidenberg Protzko Eye Associates

    Havre de Grace, Maryland, 21078, United States

  • Shettle Eye Research, Inc.

    Largo, Florida, 33773, United States

  • Total Eye Care, PA

    Memphis, Tennessee, 38119, United States

  • United Medical Research Institute

    Inglewood, California, 90301, United States

  • Visionary Research Institute

    Newport Beach, California, 92663, United States

  • Wolstan and Goldberg Eye Associates

    Torrance, California, 90505, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.